You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
绿叶制药(02186.HK):力扑素®列入新版国家医保目录
格隆汇 12-28 21:33

格隆汇 12 月 28日丨绿叶制药(02186.HK)宣布,集团的创新紫杉醇脂质体制剂—力扑素®被列入新版国家医保目录("国家医保目录")乙类范围。力扑素®说明书所有适应症,包括非小细胞肺癌、卵巢癌和乳腺癌都已获得国家医保报销。

力扑素®为集团的专利制备紫杉醇类制剂,运用创新的脂质体给药剂,用于非小细胞肺癌、卵巢癌、乳腺癌等若干类癌症的化学治疗。集团在中国持有紫杉醇脂质体的组成和配方专利。于公告日期,力扑素®为全球首个及中国唯一获批准销售的紫杉醇脂质体产品。

根据IQVIA的资料,力扑素®为2020年上半年中国第二大的国内抗癌药品,同时亦为2020年上半年中国最普遍采用的紫杉醇类产品。此前,紫杉醇脂质体已作为一线药物被写入《CSCO乳腺癌诊疗指南(2020版)》、《CSCO原发性肺癌诊疗指南(2019版)》、并被纳入《妇科恶性肿瘤紫杉类药物临床应用专家共识》、《乳腺癌中紫杉类药物临床应用专家共识(2020年)》中。此外,紫杉醇脂质体还作为多项放化疗首选联合用药入选《中国食管癌放射治疗指南(2019版)》。

董事会相信,力扑素®被纳入新版国家医保目录证明其符合国家医疗保障局对药品的的临床价值、对患者带来益处、创新程度等方面的认可,将令更多患者能够负担得起力扑素®,提升该产品在相关适应症上的渗透率,为力扑素®的长期增长注入动力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account